文献速递主动脉疾病

胸主动脉瘤与B型夹层住院、修复及死亡率的全国趋势:基于全国住院患者样本的分析

National trends in admissions, repair, and mortality for thoracic aortic aneurysm and type B dissection in the National Inpatient Sample.
PubMed 文献 · J Vasc Surg · 2018-03-02

该研究基于美国全国住院患者样本(NIS)2000至2012年155,187例胸主动脉瘤或B型夹层患者,分析住院、侵入性治疗及院内死亡趋势。胸主动脉瘤住院占比高于B型夹层(69.8% vs 30.2%,P < .001),且增长更快(132% vs 63%,P < .001)。胸主动脉瘤修复率相对稳定,B型夹层修复数量增加(P < .001),胸主动脉腔内修复术(TEVAR)应用增多,两种疾病院内死亡率均随时间稳步下降(P < .001)。

要点

  • 胸主动脉瘤住院占比高于B型夹层(69.8% vs 30.2%,P < .001),且增长更快(132% vs 63%,P < .001)。
  • 胸主动脉瘤修复率随时间保持相对稳定,但TEVAR自2006年起取代部分开放修复。
  • B型夹层修复数量增加(P < .001),TEVAR自2010年起取代开放修复,占全部夹层修复的50.5%。

核心结论

  • 胸主动脉瘤住院增加但修复率稳定,TEVAR取代部分开放修复;B型夹层住院增幅较温和但修复不成比例增加,主要因TEVAR使用增加;两种疾病院内死亡率均下降,受患者选择影响。

研究设计与样本

  • 基于国际疾病分类第九版(ICD-9)诊断与操作代码的全国住院患者样本(NIS)分析,纳入2000年至2012年155,187例胸主动脉瘤或B型夹层患者,排除A型夹层或升主动脉修复患者。

主要发现

  • 胸主动脉瘤住院占比高于B型夹层(69.8% vs 30.2%,P < .001),住院数量增长更快(132% vs 63%,P < .001)。
  • 胸主动脉瘤的TEVAR在2005年增加,与FDA批准TEVAR用于胸主动脉瘤适应症一致,2006年起取代开放修复;胸主动脉瘤修复率随时间保持相对稳定。
  • B型夹层的TEVAR在2006年增加,2010年取代开放修复,并持续占全部夹层修复的50.5%;B型夹层修复数量增加(P < .001),超过住院数量增幅。
  • 两种疾病住院患者总体院内死亡率随时间稳步下降(P < .001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The advent of endovascular repair for both thoracic aortic aneurysm and type B dissection has transformed the management of these disease processes. This study was undertaken to better define, compare, and contrast the national trends in hospital admissions, invasive treatments, and inpatient mortality of patients with thoracic aortic aneurysm and type B dissection in the National Inpatient Sample. METHODS: The cohort was derived from International Classification of Diseases, Ninth Revision diagnosis codes for thoracic aortic dissection and thoracic aortic or thoracoabdominal aortic aneurysm. Patients receiving type A dissection or ascending aortic repair during their index admission were excluded using International Classification of Diseases, Ninth Revision procedure codes. A total of 155,187 patients were available for analysis from 2000 to 2012. RESULTS: Admissions for thoracic aortic aneurysm outnumbered the admissions for type B dissection (69.8% vs 30.2%; P < .001), and the number of admissions for aneurysm grew more rapidly during this time (132% vs 63%; P < .001). Thoracic endovascular aortic repair (TEVAR) for aneurysm experienced an increase in 2005, concordant with Food and Drug Administration approval of TEVAR for thoracic aortic aneurysm indication, then superseded open repair for thoracic aortic aneurysm from 2006 onward. Despite this, the rate of thoracic aortic aneurysm repair has remained relatively stable over time. TEVAR for dissection increased in 2006, superseded open repair in 2010, and continues to account for 50.5% of all dissection repairs. Overall, the number of type B dissection repairs has increased (P < .001), over and above the increase in number of admissions for type B dissection. Despite the increased trends of utilization of TEVAR for both aneurysm and type B dissection, the overall in-hospital mortality rate among patients admitted for either disease state has decreased steadily over time (P < .001). CONCLUSIONS: Whereas admissions for thoracic aortic aneurysm disease have increased over time, the rate of aneurysm repair has been stable, although TEVAR has supplanted a proportion of open repairs. In contrast, whereas admissions for type B dissection have experienced a more modest increase, there has been a disproportionate increase in type B dissection repair, largely due to increased use of TEVAR. These results show embracing of endovascular technology for dissection through expansion of indication. Despite the increase in rate of repair for type B dissection, inpatient mortality rate was reduced in both aneurysm and dissection patients, influenced by appropriate selection of patients for intervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang GJ, Jackson BM, Foley PJ, et al. National trends in admissions, repair, and mortality for thoracic aortic aneurysm and type B dissection in the National Inpatient Sample. J Vasc Surg. 2018. PMID: 29506945. doi:10.1016/j.jvs.2017.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。